JumpStart Ventures Invests $250,000 in Thermalin Diabetes Inc.
03/29/2010
"Over the next 20 years, worldwide insulin sales are expected to grow from $12 billion to $54 billion, JumpStart Ventures partner Ted Frank told Crain's Cleveland Business. "That growth, combined with the medical community's interest in insulin with higher performance, fewer side effects, and storage flexibility, position Thermalin's pipeline to be in high demand."
Thermalin will use the funds to validate its insulin analogs' characteristics, locate a manufacturer, and proceed in the investigational drug process with the FDA.
The company's products include a faster meal-time insulin that is expected to reduce long-term side effects. The insulin can also be stored at higher temperatures, which would make transport and delivery easier.
Project Announcements
EPC-Columbia Plans Fremont, Ohio, Manufacturing Operations
11/05/2025
Aclara Resources Plans Calcasieu Parish, Louisiana, Heavy Rare Earth Separation Operations
11/04/2025
KCG Engineering Group Plans Chesapeake, Virginia, Operations
11/04/2025
Morin Establishes Little Rock, Arkansas, Operations
11/03/2025
Provalus Plans West Plains, Missouri, Operations
11/01/2025
Eos Energy Enterprises Expands Allegheny County, Pennsylvania, Operations
11/01/2025
Most Read
-
2025’s Top States for Business: How the Winners Are Outpacing the Rest
Q3 2025
-
The Compliance Reckoning Is Here
Q3 2025
-
Around the Horn: Data Center Supply Chains — What's Next?
Q3 2025
-
How Consumer Trends Are Reshaping Food Facilities
Q3 2025
-
First Person: Filter King’s Expansion Playbook
Q3 2025
-
Rethinking Auto Site Strategy in the Age of Tariffs and Powertrain Shifts
Q3 2025
-
How Canada Stays Competitive
Q3 2025